Elite Pharmaceuticals (OTCMKTS:ELTP) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of high‐quality generic and proprietary drug products. The company’s operations encompass formulation development, analytical testing, regulatory support and commercial launch activities. Elite Pharmaceuticals places particular emphasis on niche therapeutic areas where it can leverage its expertise in dosage form design and controlled‐substance handling.
Elite’s product portfolio includes oral solids, semi‐solids, liquids and specialized controlled‐release formulations. Key therapeutic segments served by the company include pain management, respiratory therapy, hormone replacement and central nervous system indications. Through both in‐house development and strategic licensing arrangements, Elite Pharmaceuticals has built a diversified pipeline of abbreviated new drug applications (ANDAs) targeting complex generics and limited competition markets.
Headquartered in Newtown, Pennsylvania, Elite Pharmaceuticals serves customers across the United States through relationships with national wholesalers, specialty pharmacies and healthcare institutions. The company also maintains international partnerships to distribute select products in regions such as Latin America and the Asia‐Pacific, leveraging its regulatory and manufacturing capabilities to meet varying market requirements.
Founded in 2005, Elite Pharmaceuticals is led by a management team with deep experience in pharmaceutical development, regulatory affairs and manufacturing operations. Under the leadership of CEO Thomas M. Droll and a seasoned executive team, the company continues to expand its product offerings and strengthen its presence in targeted therapeutic niches, while adhering to stringent quality and compliance standards.
AI Generated. May Contain Errors.
Free ELTP Stock Alerts